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DObjectives: The Trifecta valve (St Jude Medical, St Paul, Minn) is a new bioprosthetic heart valve designed for
supra-annular aortic valve replacement. We compared the hemodynamic performance of the Trifecta against the
Perimount-Magna and Magna-Ease valve prostheses (Edwards Lifesciences, Irvine, Calif) in a nonrandomized,
observational, single-center study.
Methods: A total of 346 consecutive patients with aortic valve disease underwent aortic valve replacement
between January 2003 and November 2011, with implantation of the Trifecta (group 1, n ¼ 121), the
Perimount-Magna (group 2, n ¼ 126), or the Magna Ease bioprosthesis (group 3, n ¼ 99). Clinical and
hemodynamic data were prospectively recorded and compared. Hemodynamic performance was evaluated by
transthoracic echocardiography, including mean pressure gradient (MPG) and aortic valve area (AVA) at
baseline, discharge, and 6-month follow-up. A multivariate model of covariance analysis was constructed to
further compare the primary study end points of MPG and AVA at 6-month follow-up.
Results: For all valve sizes, unadjusted MPGs did not differ (P ¼ .08), but AVAs differed (P<.001) between
groups at 6-month follow-up. After final adjustment by a multivariate model of covariance analysis, neither the
MPGs (P¼ .16) nor theAVAs (P¼ .92) at 6months postoperativelywere influenced by the type of prosthesis used.
Conclusions: The present observational study is the first to compare the new Trifecta valve with well-
established supra-annular aortic valve bioprostheses from a hemodynamic perspective. Although mean pressure
gradients and aortic valve areas seem to be advantageous at 6-month follow-up with the new Trifecta valve, after
multivariate covariance analysis, no influence of prosthesis type on mean pressure gradient or aortic valve area
could be demonstrated. (J Thorac Cardiovasc Surg 2014;147:1553-60)Many commercially available aortic valve substitutes have
undergone design modifications over the years, including
the supra-annular Carpentier-Edwards Perimount Magna
and Perimount Magna Ease (Edwards Lifesciences, Irvine,
Calif) bioprostheses, which represent further development
of the original Carpentier-Edwards Perimount bioprosthetic
heart valve.1,2 In several previous studies, the hemodynamic
performance and clinical results of the Perimount valve
have been excellent.3-7 Recently, a novel supra-annular aor-
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The Journal of Thoracic and CarPaul, Minn) valve, has been launched. Great emphasis has
been placed on various determinants of prosthetic valve
performance, including aortic valve area, pressure gradi-
ents, and durability. Detailed hemodynamic data on the
Trifecta aortic valve bioprosthesis have been released by
the manufacturer, but it has not yet been investigated
extensively or independently.8
This study aims to compare the hemodynamic perfor-
mance of these next-generation supra-annular aortic valve
bioprostheses in a single-center observational study.METHODS
Study Design
This study was an observational, single-center, cohort study of 346
consecutive patients who underwent surgical aortic valve replacement at
the West-German Heart Center Essen between January 2003 and
November 2011. Patients received the Trifecta (group 1, n ¼ 121), the
Carpentier-Edwards Perimount Magna (group 2, n ¼ 126), or the
Carpentier-Edwards Perimount Magna Ease (group 3, n ¼ 99) bioprosthe-
sis, depending on surgeon and patient preference. After sizing the annulus
with the relevant commercial sizer, the prosthesis size was carefully
chosen according to the prosthesis-patient mismatch (PPM) chart provided
by the manufacturer. According to our institutional policy, an implanted
prosthesis should provide an effective orifice area index (EOAI) of at least
more than 0.85 cm2/m2 to prevent potential PPM.9 Surgical aortic valve
replacement was routinely performed, as previously described, in alldiovascular Surgery c Volume 147, Number 5 1553
Abbreviations and Acronyms
ANOVA ¼ analysis of variance
AVA ¼ aortic valve area
CABG ¼ coronary artery bypass grafting
CPB ¼ cardiopulmonary bypass
EOAI ¼ effective orifice area index
EuroSCORE ¼ European System for Cardiac
Operative Risk Evaluation
MPG ¼ mean pressure gradient
STS ¼ Society of Thoracic Surgeons
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Dpatients using median sternotomy, a standard cardiopulmonary bypass
(CPB) technique with ascending aortic and venous cannulation, mild
hypothermia (>32C), and cold crystalloid cardioplegic arrest.10 Echocar-
diographic examinations were performed preoperatively, at discharge, and
at 6-month follow-up.
All patients who underwent isolated aortic valve replacement were in-
cluded in the present study. Patients requiring redo aortic valve replacement
or concomitant surgical procedures, such as (1) myectomy, (2) aortic root
enlargement, (3) surgery of the ascending aorta and/or coronary artery
bypass grafting, and/or (4) additional valve surgery (mitral valve repair/
replacement or tricuspid valve repair/replacement), were also included.
Ethics approval was granted by the Institutional Review Board, accord-
ing to the Declaration of Helsinki. All of the patients had previously
granted permission for use of their medical records for research purposes.
The primary study end points were mean pressure gradients and aortic
valve area at 6-month follow-up. The secondary end point was the influence
of prosthesis type on mean pressure gradients and aortic valve area at
6 months after adjustment by a multivariate model of covariance analysis.
Data Collection and Follow-up
Patient demographics and operative data were recorded in a prospective
institutional database and retrospectively extracted and evaluated. Perioper-
ative deaths (30-daymortality) were tracked from the institutional database
or by active follow-up. All surviving patients were contacted on a routine
basis and underwent a comprehensive echocardiographic examination 6
months postoperatively at theWest-German Heart Center Essen. Discharge
echo-data could be obtained in 51 patients of group 1, 39 patients of group 2,
and 69 patients of group 3. The 6-month echo-data were available in 79
patients of group 1, 82 patients of group 2, and 56 patients of group 3.
Echocardiography
Transthoracic 2-dimensional echocardiographic standard views were
obtained in a left lateral supine position using a standard ultrasound system
with a 3.5-MHz (S5-1) probe (iE33; Philips Medical Systems, Andover,
Mass). Left ventricular dimensions were measured according to the recom-
mendations of the American Society of Echocardiography. Doppler flow
data were acquired from the left ventricular outflow tract region in the
pulsed-wave mode, and from the aortic valve in the continuous-wave
mode in the apical 5-chamber view. The modified Bernoulli equation
was used to calculate peak and mean pressure gradients (MPGs) across
the prosthetic valve.
Statistics
Descriptive statistics are summarized for categorical variables as
frequencies and percentages. Continuous variables are reported as mean 
SD. New York Heart Association class is presented as a median. Groups
were compared using Pearson c2 tests for categorical variables and 1-way
analysis of variance (ANOVA) for continuous variables. Mean pressure1554 The Journal of Thoracic and Cardiovascular Surgradients and aortic valve areas were compared using 1-way ANOVA and,
in addition, pairwise comparisons were performed using the Student t-test
if a significance of .05was observedwith theANOVA.Amultivariatemodel
of covariance analysis was constructed to further compare the primary study
end points of MPG and aortic valve area (AVA) at 6-month follow-up. The
following preoperativevariableswere used for the regression analysis: group
membership (model of the implanted valve type), sex, age, body height and
body weight, body surface area, serum creatinine level, the Society of
Thoracic Surgeons (STS) score, European System for Cardiac Operative
Risk Evaluation (EuroSCORE), EOAI, concomitant coronary artery bypass
grafting (CABG) surgery, concomitant valve surgery, left ventricular
ejection fraction, and New York Heart Association functional class. Those
variables identified by the univariate analysis with P< .1 were added to
the multivariable model, in addition to the model of implanted prosthesis.
In general, P<.05 indicated statistical significance. All statistical analyses
were performed using SAS, version 9.2 (SAS Inc, Cary, NC). The authors
had full access to and take full responsibility for the integrity of the data.
All authors have read and agreed to the article as written.RESULTS
Preoperative characteristics of the 3 groups are summa-
rized in Table 1. The groups differed for all listed variables,
except for age, body mass index, chronic obstructive pul-
monary disease, renal disease, diabetes, existing coronary
artery disease, and previous cardiac surgery. Preoperative
MPGs were higher in group 1 than in groups 2 and 3
(48.7  17.0 vs 43.8  19.3 vs 45.1  20.8 mm Hg;
P<.001). Preoperative risk assessment, as measured by lo-
gistic EuroSCORE and STS score, indicated a lower level of
risk for patients in group 1 than for the other groups (logistic
EuroSCORE: 15.8%  13.5% vs 19.8%  15.1% vs
19.6%  10.7% [P ¼ .005]; and STS score: 4.7% 
5.8% vs 9.2%  7.5% vs 13.2%  12.0% [P<.001]).
Intraoperative variables are listed in Table 2. Aortic
cross-clamp time (85  30 vs 97  34 vs 88  33 minutes;
P ¼ .012) and CPB times (127  52 vs 142  54 vs 131 
39 minutes; P ¼ .002) differed significantly between the
groups, with highest aortic cross-clamp and CPB times in
group 2. Concomitant valve surgery, including additional
surgery on the mitral and tricuspid valves, was more
common in group 1 than groups 2 and 3 (32.2% vs
18.3% vs 16.1%; P ¼ .005). All groups had similar rates
of concomitant CABG surgery (P ¼ .52). Group 2 showed
a significantly higher percentage of additional aortic root
enlargement than groups 1 and 3 (25.4% vs 9.1% vs
12.1%; P ¼ .002). Patients in group 2 also had a higher
rate of additional septal myectomy than those in groups
1 and 3 (59.5% vs 19.8% vs 35.4%; P< .001). In 21%
(n ¼ 19) of the patients in group 1, in 23% (n ¼ 30) of
the patients in group 2, and in 1% (n ¼ 1) of the patients
in group 3 (P<.01), the choice of valve prosthesis resulted
in moderate prosthesis-patient mismatch, as defined by an
EOAI of 0.65 to 0.85 cm2/m2. Of those patients in the
PPM category, the mean EOAI was 0.81  0.01 cm2/m2
(minimum, 0.74 cm/m2) in group 1, 0.82  0.02 cm2/m2
(minimum, 0.80 cm/m2) in group 2, and 0.79 cm2/m2gery c May 2014
TABLE 1. Patient baseline characteristics
Variable Group 1 (n ¼ 121) Group 2 (n ¼ 126) Group 3 (n ¼ 99) P value
Demographics
Age, y 72.2  6.7 75.2  7.4 73.2  7.3 .06
Female sex 36 (29.8) 43 (34.1) 48 (48.5) .004
BMI, kg/m2 26.9  6.7 26.6  4.4 27.8  4.6 .31
BSA, m2 1.9  0.3 1.8  0.2 1.8  0.3 .02
Risk factors and comorbidities
NYHA class, median (range) III (II-IV) III (II-IV) III (II-IV) —
Peripheral vascular disease 25 (20.7) 39 (31.0) 8 (8.1) <.001
Systemic hypertension 92 (76.0) 118 (93.7) 92 (92.9) .006
COPD 22 (18.2) 27 (21.4) 23 (23.2) .47
Renal disease (serum creatinine>200 mmol/L) 11 (9.1) 21 (16.6) 18 (18.1) .11
Diabetes mellitus 35 (28.9) 37 (29.4) 27 (27.3) .09
Cardiac history
LV-EF,% 50.5  13.4 55.2  12.9 51.1  10.6 <.001
LV-EF<35% 12 (9.9) 9 (7.1) 4 (4.0) <.001
Pulmonary hypertension 17 (14.0) 40 (31.7) 29 (29.3) .003
Coronary artery disease 78 (64.5) 81 (64.3) 67 (67.7) .59
Preoperative AVA, cm2 0.86  0.35 0.86  0.37 0.76  0.28 .016
Preoperative MPG, mm Hg 48.7  17.0 43.8  19.3 45.1  20.8 <.001
Previous cardiac surgery 7 (5.8) 13 (10.3) 4 (4.0) .65
Atrial fibrillation 21 (17.4) 14 (11.1) 13 (13.1) .01
Risk scores
STS score,% 4.7  5.8 9.2  7.5 13.2  12.0 <.001
Logistic EuroSCORE,% 15.8  13.4 19.8  15.1 19.6  10.7 .005
Data are presented as mean  SD or number (%). BMI, Body mass index; BSA, body surface area; NYHA, New York Heart Association; COPD, chronic obstructive pulmonary
disease; LV, left ventricle; EF, ejection fraction; AVA, aortic valve area; MPG, mean pressure gradient; STS, Society of Thoracic Surgeons; EuroSCORE, European System for
Cardiac Operative Risk Evaluation.
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cording to the PPM charts provided by manufacturers
gave values of 1.0  0.1cm2/m2 for group 1, 0.9 
0.1cm2/m2 for group 2, and 0.9  0.1cm2/m2 for group 3,
for all valve sizes (P ¼ .001). Only patients in group 1
received 19-mm (n ¼ 6), 27-mm (n ¼ 10), and 29-mm
(n ¼ 4) prostheses. Comparing the remaining valve sizes,
the implantation of 21- and 23-mm valve prostheses wasTABLE 2. Intraoperative data
Variable Group 1 (n ¼ 121
ACC time, min 85  30
CPB time, min 127  52
Concomitant valve surgery* 39 (32.2)
Concomitant CABG 65 (53.7)
Aortic root enlargement 11 (9.1)
Septal myectomy 24 (19.8)
Implanted valve size, mm
19 6 (4.9)
21 26 (21.5)
23 41 (33.9)
25 34 (28.1)
27 10 (8.3)
29 4 (3.3)
Theoretical EOAI of implanted valve according to
manufacturer, cm2/m2
1.0  0.1
Data are presented as mean SD or number (%). ACC, Aortic cross-clamp time; CPB, car
area index. *Concomitant valve surgery includes concomitant tricuspid and mitral valve s
The Journal of Thoracic and Carmore common in group 2 (P< .03 and P< .001, respec-
tively), whereas the implantation of a 25-mm valve was
more common in group 1 (P<.001).
Postoperative Outcomes
There was no difference in intraoperative mortality be-
tween the 3 groups. Only 1 patient died intraoperatively,
in group 1. The 30-day mortality was 8.3% (10/121) in) Group 2 (n ¼ 126) Group 3 (n ¼ 99) P value
97  34 88  25 .012
142  54 131  39 .002
23 (18.3) 16 (16.1) .005
76 (60.3) 60 (60.6) .52
32 (25.4) 12 (12.1) .002
75 (59.5) 35 (35.4) <.001
— — —
43 (34.1) 30 (30.3) .03
70 (55.6) 48 (48.5) <.001
13 (10.3) 21 (21.2) <.001
— — —
— — —
0.9  0.1 0.9  0.1 .001
diopulmonary bypass; CABG, coronary artery bypass grafting; EOAI, effective orifice
urgery.
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FIGURE 1. Mean pressure gradients (MPGs) at discharge (A) and at the 6-month follow-up (B). Black bars, Group 1; white bars, group 3; gray bars,
group 2.
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(7/99) in group 3 (P ¼ .04).
Hemodynamic Outcomes
Unadjusted mean pressure gradients for all valve sizes at
discharge were 9.1  3.9 mm Hg in group 1 compared with
11.2 4.1mmHg in group 2 and 14.0 5.0mmHg in group
3 (P ¼ .01). At the 6-month follow-up, mean pressure
gradients for all valve sizes were 8.9  3.9 mm Hg in group
1 compared with 10.8  4.7 mm Hg in group 2 and 11.4 
3.1 mm Hg in group 3 (P ¼ .08). Because size distribution
between the groupswas different, not surprisingly, the overall
aortic valve areas at discharge were 1.8 0.4 cm2 in group 1
compared with 1.6 0.5 cm2 in group 2 and 1.5 0.3 cm2 in
group 3 (P < .001); at the 6-month follow-up, aortic
valve areas were 2.1  0.5 cm2 in group 1 compared with
1.6  0.5 cm2 in group 2 and 1.7  0.3 cm2 in group
3 (P ¼ .004). A detailed breakdown of MPGs and AVAs at
discharge and 6-month follow-up for each valve size is
presented inFigures 1 and 2 (19-, 27-, and 29-mmbioprosthe-
ses only implanted in group 1).
Regression Analysis
To further control for study bias, a multivariate model of
covariance analysis was constructed based on 14 major risk
factors, to evaluate possible factors influencing the primary
study end points of MPG and AVA at the 6-month follow-up
(Table 3). In the univariate model, the following variables1556 The Journal of Thoracic and Cardiovascular Surwere strongly associated with MPGs at 6-month follow-
up: sex, patient’s height, EOAI, and, most notably, the
implanted prosthesis type (Table 4). Within the univariate
model, AVAs at 6 months were also influenced by the
prosthesis type, sex, height, EOAI, and, in addition, weight,
body surface area, STS score, concomitant CABG surgery,
and left ventricular ejection fraction. At the 6-month
follow-up, neither MPGs nor AVAs were influenced by
the tested variables. More important, after final adjustment,
MPGs (P¼ .16) and AVAs (P¼ .92) were not influenced by
the model of implanted prosthesis.DISCUSSION
The present study is the first, to our knowledge, to
compare the new Trifecta valve with 2 well-established
supra-annular aortic valve bioprostheses regarding hemo-
dynamic results at 6-month follow-up. This study provides
several interesting findings. In patients undergoing surgical
aortic valve replacement with bovine pericardial valve
substitutes, receiving the Trifecta, the Carpentier-Edwards
Perimount Magna, or the Magna Ease bioprosthesis, hemo-
dynamic results showed the following:
1. All evaluated bioprostheses had favorable mean pressure
gradients and aortic valve areas at 6-month follow-up.
2. No significant difference existed between the 3 groups
regarding mean pressure gradients (for all valve sizes)
at 6-month follow-up.gery c May 2014
FIGURE 2. Aortic valve areas (AVAs) at discharge (A) and at the 6-month follow-up (B). Black bars, group 1; white bars, group 3; gray bars, group 2.
TABLE 4. Univariate covariance analysis of variables associated with
MPG and AVA
Univariate analysis
MPG AVA
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Trifecta valve (for all valve sizes) at 6-month follow-up.
4. After adjustment by multivariate covariance analysis,
the implanted prosthesis type could not be identified
as an independent factor influencing mean pressure
gradients or aortic valve area at 6-month follow-up.
Conventional surgical aortic valve replacement with
bioprosthetic aortic valves is a well-established procedure,
and the advantages and disadvantages of these valves are
well known.11 In contrast to mechanical valves, biologicalTABLE 3. Multivariate covariance analysis of variables associated
with MPG and AVA
Variable
Multivariate analysis
MPG AVA
F-statistic P value F-statistic P value
Group membership 1.85 .160 0.10 .902
Sex 1.01 .317 0.13 .721
Height 2.05 .154 0.07 .795
Weight — — 0.31 .578
BSA — — 0.44 .507
STS score — — 0.31 .578
EOAI 3.30 .071 0.24 .627
Concomitant valve surgery — — 1.93 .167
LV-EF — — 1.11 .295
MPG, Mean pressure gradient; AVA, aortic valve area; BSA, body surface area; STS,
Society of Thoracic Surgeons; EOAI, effective orifice area index; LV, left ventricle;
EF, ejection fraction.
The Journal of Thoracic and Carvalves do not require anticoagulation therapy, but they do
have a limited life span because of potential structural valve
deterioration; so far, they have to compete with the larger
AVAs afforded by mechanical valves.11 At present,Variable F-statistic P value F-statistic P value
Group membership 6.57 .001 14.82 <.001
Sex 8.73 .004 14.62 <.001
Age 2.14 .145 0.53 .466
Height 6.94 .009 27.20 <.001
Weight 0.14 .714 8.247 .005
BSA 0.42 .517 16.71 <.001
Creatinine 0.27 .605 0.11 .743
STS score 2.90 .090 7.18 .008
EuroSCORE 3.59 .056 0.08 .777
EOAI 5.73 .018 3.93 .049
Concomitant valve surgery 0.16 .694 2.13 .147
Concomitant CABG surgery 2.14 .145 4.82 .029
LV-EF 0.96 .328 4.86 .029
NYHA 0.96 .412 0.25 .859
MPG, Mean pressure gradient; AVA, aortic valve area; BSA, body surface area; STS,
Society of Thoracic Surgeons; EuroSCORE, European System for Cardiac Operative
Risk Evaluation; EOAI, effective orifice area index; CABG, coronary artery
bypass grafting; LV, left ventricle; EF, ejection fraction; NYHA, New York Heart
Association.
diovascular Surgery c Volume 147, Number 5 1557
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because of increased durability, ease of implantation, and
improved hemodynamics, leading to increased implanta-
tion of these valves in younger patients (aged approximately
60 years).11-13 This trend has motivated many companies to
enhance existing models or develop new stented pericardial
aortic valve bioprostheses. The new Trifecta valve
(St Jude Medical) represents one of the company’s latest
developments, and in contrast to other stented
bioprostheses available, similar to the Mitroflow valve,
goes back to a previous concept of externally mounted
leaflet tissue. The hemodynamic performance of the
Trifecta valve has not been investigated in detail. It,
therefore, seems logical to compare the Trifecta valve
with other well-established next-generation supra-annular
aortic valve bioprostheses. Great emphasis has been placed
on various determinants of valve performance, including
aortic valve, pressure gradients, and durability, by all
manufacturers. Regardless of which prosthesis is being
assessed, data on valve hemodynamics should be obtained
at least 6 months postoperatively, to limit the bias of
hemodynamic instability in the immediate postoperative
course.14 Therefore, we decided to analyze valve per-
formance of the Trifecta, Carpentier-Edwards Perimount
Magna, and Magna Ease bioprostheses, including follow-
up echocardiographic data at 6 months.
Excellent hemodynamic results have been reported for
supra-annular aortic bioprostheses, including the
Carpentier-Edwards Perimount Magna and the Magna
Ease.4-7,10,13,15 To the best of our knowledge, the present
study represents the first hemodynamic comparison
between the bovine, pericardial Trifecta, Carpentier-
Edwards Perimount Magna, and Magna Ease prostheses.
Just recently, an initial experience evaluating the Trifecta
valve in a single-center study has been published.8 In this
single-center study, the Trifecta valve was implanted in 70
patients, and in 19 patients, the authors evaluated the hemo-
dynamic performance during the direct postoperative
course, including echocardiographic data at discharge.
The published MPGs of the Trifecta valve at discharge
are comparable to those values shown in this present study.8
The 6-month follow-up data of the present study demon-
strate excellent mean pressure gradients for all valve
sizes in the 3 groups, without any statistically significant
differences. In addition, the results of Dell’Aquila and
colleagues8 support our valve size–specific results of
MPGs for the Trifecta valve at the 6-month follow-up.
As alreadymentioned, theTrifecta bioprosthesis goes back
to the concept of externalmounted pericardium, similar to the
Mitroflow prosthesis, the only other 1 prosthesis with an
external mounted pericardium. The hemodynamic perfor-
mance of the pericardialMitroflow valve is well documented
in the literature.16 Suri and colleagues15 recently published
a randomized trial evaluating the hemodynamic performance1558 The Journal of Thoracic and Cardiovascular Surof the Edwards Perimount Magna, the Sorin Mitroflow, and
the St Jude Epic bioprostheses. They could show excellent
hemodynamic results, as revealed by dismissal echocardiog-
raphy on postoperative day 4 for all randomized third-
generation porcine and pericardial valves.15 Over all valve
sizes, the results of Suri and colleagues are more or less
consistent with our results regarding AVA and MPG.
However, the authors could show small, but consistent, early
postoperative hemodynamic differences, with slightly lower
MPGs and higher AVAs for the Magna valve.
Concerning the hemodynamics of the Mitroflow prosthe-
sis, Jamieson and colleagues17 published detailed documen-
tation of the hemodynamic performance of the Mitroflow
bioprosthesis in 2010. This study of 55 patients from
a Canadian multicenter evaluation provides the opportunity
to develop reference-effective orifice areas (EOAs) for the
Mitroflow prosthesis.17 The mean EOAs were 1.4 cm2 for
the 19-mm valve, 1.4 cm2 for the 21-mm valve, and
1.8 cm2 for the 23- and 25-mm valves. The corresponding
mean pressure gradients for the Mitroflow prosthesis were
8.6 mm Hg for the 19-mm valve, 10 mm Hg for the
21-mm valve, 8.5 mm Hg for the 23-mm valve, and
7.5 mm Hg for the 25-mm valve.17 These results of Jamie-
son and colleagues17 showed excellent hemodynamic
results of theMitroflow prosthesis compared with the valves
tested in the present study, especially when comparing
mean pressure gradients. Moreover, for the small aortic
annulus, the Mitroflow prosthesis offers excellent hemody-
namics, with mean pressure gradients of 8.6 mm Hg for the
19-mm valve, as documented in 13 patients.17 However,
these results are not comparable to the present study,
because only six patients in the Trifecta group received
a 19-mm valve. On the other hand, another study by Conte
and colleagues18 evaluated the Mitroflow bioprosthesis in
a large, prospective, multicenter trial. Within this study,
echocardiography at 1 year showedmean pressure gradients
ranging between 7.3 and 13.4 mm Hg and EOAs ranging
between 1.05 and 1.82 cm2 (for all valve sizes), which are
more comparable to our results. In detail, the Mitroflow
bioprosthesis showed mean pressure gradients of 13.4 mm
Hg for the 19-mm valve, 11.5 mm Hg for the 21-mm valve,
10.6 mm Hg for the 23-mm valve, 8.6 mm Hg for the
25-mm valve, and 7.3 mm Hg for the 27-mm valve.18
Comparing the results of the Mitroflow prosthesis with
those of the present study, over all valve sizes, the results
of Jamieson17 and Conte18 and colleagues are more or
less consistent with our results regarding AVA and MPG,
with slightly better results favoring the tested valves of
the present study. As an example, Conte and colleagues18
reported EOAs for the size 23-mm Mitroflow prosthesis
of 1.37 cm2 in 194 patients, whereas we observed EOAs
of 1.73 cm2 for the Perimount Magna Ease, 1.65 cm2 for
the Perimount Magna, and 2.16 cm2 for the Trifecta valve
at the 6-month follow-up.gery c May 2014
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regarding implanted valve sizes. Most of the patients across
all 3 groups received a 21-, 23-, or 25-mm prosthesis. In
every single case, the valve size was carefully chosen to
guarantee an EOAI greater than 0.85 cm2/m2, which is
predicated by a theoretical, calculated EOAI of approxi-
mately 0.9 cm2/m2. However, in some patients, a mild
prosthesis-patient mismatch, resulting in a mean value of
approximately 0.82 cm2/m2, was accepted, which was
most frequent in group 2 and least frequent in group 3. In
just 1 patient of the 346 included, a minimum theoretical
indexed orifice area index of 0.74 cm2/m2 was observed.
In line with these observations, additional aortic root
enlargement to prevent patient-prosthesis mismatch was
significantly more common in group 2 (P ¼ .01) than in
the other groups. Whenever necessary to guarantee an
appropriate prosthesis size, an aortic root enlargement
was performed in all groups, irrespective of prosthesis
type. However, as indicated in Table 2, many concomitant
procedures were performed in all groups, and in some cases,
the surgeon decided to avoid aortic root enlargement to
keep cross-clamp times as short as possible in individual,
complex cases. In 20% to 60% of patients across all
groups, an additional myectomy was performed, thereby
eliminating the potential subvalvular influence on the
transvalvular pressure gradients. As a result, subvalvular
influence on postoperative transvalvular aortic gradients
can be excluded in our results. Interestingly, additional
root enlargement was least common in group 1. One could
conclude that the Trifecta provides larger aortic valve areas
than other stented bovine pericardial supra-annular bio-
prostheses; however, there are no reproducible scientific
data available to verify such assumptions. One could,
however, speculate about the underlying mechanisms for
potential larger aortic valve areas offered by the Trifecta
valve. The Trifecta is engineered such that the externally
mounted pericardial tissue offers larger orifice areas
because of the externally mounted tissue. In our institution,
the valve size decision is made intraoperatively based on
PPM charts provided by the manufacturer, to choose a valve
size that is less likely to result in PPM. The surgeon is,
therefore, reliant on the PPM charts provided by the
manufacturers, and these charts are not consistent and
comparable between manufacturers. There are discrep-
ancies between the cutoff values used to define PPM,
depending on whether the definitions of Pibarot19-22 or
Rao23 and colleagues are followed, and somemanufacturers
have based their recommendations only on in vitro valve
evaluations or preliminary short-term follow-up data.
Recommendations should be based on large-scale in vivo
studies, which were thankfully usually the case. In addition,
independent in vitro evaluations of all new valves are
mandatory to compare their hemodynamic performance
under optimal conditions.1The Journal of Thoracic and CarThe 30-day mortality was relatively high across all
groups, with 8.3% in group 1, 15% in group 2, and 7.1%
in group 3. However, the high estimated risk scores and
the large volume of additional, concomitant procedures
should be kept in mind (>50% received additional
CABG, and 32% of the patients in group 1, 18% of the
patients in group 2, and 16% of the patients in group 3
underwent additional mitral and/or tricuspid valve surgery).
The average age in this patient cohort was higher than might
have been expected, representing the increasing number of
elderly patients undergoing combined cardiac surgery, and
this may also have had an impact on the mortality rate.
Similar in-hospital mortality (16.7%) has been reported
by Bloomstein and colleagues24 in geriatric patients
undergoing aortic valve replacement (mean age, 76  4.7
years).
Limitations
Our study was performed at a single tertiary care medical
center with a relatively small sample size; however, it
represents the largest patient group treated with the Trifecta
valve to date. Moreover, the study was retrospective and,
most notably, was not randomized; therefore, the 3 groups
differed significantly, as reflected by the preoperative
characteristics. The high percentage of concomitant proce-
dures (CABG or additional valve surgery) within the groups
may have biased the results, and an analysis in patients
undergoing isolated aortic valve replacement would be
more pertinent, especially in valve sizes of less than 21
mm. However, regardless of concomitant procedures, the
hemodynamic performance of the aortic bioprostheses
should be reproducible at the 6-month follow-up.Moreover,
the higher AVAs within the Trifecta group might be biased
by an unequal size distribution. One could speculate that
if there were adequate numbers of each valve size by
prosthesis size, this finding might not have been identified.
CONCLUSIONS
To our knowledge, this study is the first to compare the
new Trifecta valve with 2 well-established supra-annular
aortic valve bioprostheses regarding their hemodynamic
results at the 6-month follow-up. All companies are in
a period of extensively promoting their products and
emphasizing their unique features. We observed excellent
mean pressure gradients and aortic valve areas for all
implanted prostheses at the 6-month follow-up. For all
implanted valve sizes, we observed higher aortic valve areas
for the Trifecta valve at the 6-month follow-up; however,
after adjustment by multivariate covariance analysis, the
implanted prosthesis type could not be identified as an
independent factor influencing mean pressure gradients or
aortic valve areas at 6 months postoperatively. The Trifecta
valve represents a completely new product (Conformite
Europeenne [CE] mark approval since 2010) within thediovascular Surgery c Volume 147, Number 5 1559
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Darmamentarium of cardiac surgeons, which can legitimately
compete with other well-established aortic valve biopros-
theses. However, the Perimount valve has the advantage
of proven long-term follow-up, which has yet to be investi-
gated in the Trifecta valve. Therefore, before advocating
a specific valve bioprosthesis, further randomized studies
evaluating the long-term durability, performance, and
valve-related morbidity of these new and innovative
biological aortic valve prostheses are needed, which should
include detailed echocardiographic data. In light of the
available evidence, none of the prostheses studied can be
recommended as being superior to their competitors.References
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